Biologic therapeutics can trigger neutralizing antibodies because the immune system recognizes the therapeutic protein as foreign and mounts a targeted response that blocks its activity. Regulatory and scientific authorities emphasize this risk: G. Shankar, US Food and Drug Administration recommends a risk-based assessment of immunogenicity, and Hubert Schellekens, Sanquin Research and University of Utrecht has documented how structural differences between therapeutic proteins and endogenous counterparts increase immune recognition. Understanding why these responses occur clarifies both clinical decision-making and regulatory oversight.
Biological and product drivers
Several product-related factors create or amplify immunogenicity. Subtle sequence changes or nonhuman glycosylation can introduce new epitopes that the adaptive immune system recognizes. Protein aggregation concentrates repeated structural motifs that stimulate B-cell activation, a mechanism described by Saskia Hermeling, Leiden University. Formulation components, impurities from manufacturing, and even container materials can act as adjuvants or modify the protein to be more immunogenic; the European Medicines Agency reported that formulation and device changes were linked to increased anti-erythropoietin antibodies in a notable clinical case. Route and frequency of administration also matter: subcutaneous delivery and intermittent dosing often carry higher immune risk than continuous intravenous infusion, although individual outcomes vary.
Patient, clinical, and societal consequences
Patient-specific factors shape responses: HLA type, prior exposure to similar antigens, age, and concomitant immunosuppression modify the probability and magnitude of antibody formation, a pattern reviewed by Alan S. Rosenberg, Amgen. Clinically, neutralizing antibodies can cause loss of efficacy, necessitating dose escalation or therapeutic switching, and in rare cases produce severe safety events such as pure red cell aplasia from anti-erythropoietin antibodies documented by regulatory agencies. Beyond individual patients, immunogenicity has cultural and territorial implications: pharmacovigilance capacity and access to alternative biologics differ between regions, and public trust can be affected when adverse immune events emerge. Mitigation combines protein engineering to remove immune epitopes, stringent manufacturing to minimize aggregates and impurities, and robust surveillance and assay strategies advocated by regulators. These layered approaches aim to balance innovation with patient safety across diverse healthcare settings.